Inflammations has been increasingly identified as a major risk factor across many disease areas particularly in Cardiovascular, immunological and auto-immune diseases. We have extensive experience in Phase 2 to Phase 3 clinical trials including major outcome studies involving anti-inflammatory drugs. Our deep understanding of key inflammatory biomarkers and safety parameters helps in efficient clinical trials designs.
We have extensive experience in Statistics, Data management, Clinical Operations and Field Monitoring from Phase 2 to Post marketing studies. Our experience include:
- Inflammatory bowel disease
- Psoriatic arthritis